Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography

European Journal of Pharmacology

Volumn 696, Issue 1-3, 2012, Pages 18-27

  Bauer, Florian ^a   Wanek, Thomas ^b   Mairinger, Severin ^a,b,c   Stanek, Johann ^b,c   Sauberer, Michael ^b   Kuntner, Claudia ^b   Parveen, Zahida ^c   Chiba, Peter ^c   Müller, Markus ^c   Langer, Oliver ^b,c   Erker, Thomas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood brain barrier; HM30181; Microdosing; P glycoprotein; Positron emission tomography; Tariquidar

Indexed keywords

2 [4 [5 [4 (BENZYLOXY) 5 METHOXY 2 NITROPHENYL] 2H TETRAZOL 2 YL]PHENETHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE; 5 (BENZYLOXY) 2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H)YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4 METHOXYANILINE; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; HM 30181; MULTIDRUG RESISTANCE PROTEIN; N [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H)YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H)YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE C 11; N' [4 (BENZYLOXY) 5 METHOXY 2 NITROBENZYLIDENE] 4 METHYLBENZENE SULFONOHYDRAZIDE; O BENZYL N [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H)YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE; O DESMETHYL N [2 [2 [4 [2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H)YL)ETHYL]PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE; PLACEBO; PROTEIN INHIBITOR; RHODAMINE 123; TARIQUIDAR; TARIQUIDAR C 11; TRACER; UNCLASSIFIED DRUG; VERAPAMIL C 11;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN LEVEL; BREAST TUMOR; COMPUTED TOMOGRAPHY SCANNER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG MICRODOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; IC 50; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIODIAGNOSIS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOPYRANS; BLOOD-BRAIN BARRIER; BREAST NEOPLASMS; FEMALE; ISOQUINOLINES; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; TETRAZOLES;

EID: 84869094982     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.09.013     Document Type: Article

References (39)

1. 11C] verapamil in epilepsy patients Eur. J. Nucl. Med. Mol. Imaging 35 2008 116 123 (Pubitemid 350234143)
2. S. Agarwal, A.M. Hartz, W.F. Elmquist, and B. Bauer Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up Curr. Pharm. Des. 17 2011 2793 2802
3. Ashworth, P.A.; Hunjan, S.; Pretswell, I.A.; Ryder, H.; Brocchini, S.J.; 1996. Piperazine-2,5-dione Derivatives as Modulators of Multidrug Resistance. PCT Int. Appl. WO 96/20180.
4. Bang, K.C.; Cha, M.Y.; Ahn, Y.G.; Ham, Y.J.; Kim, M.S.; Lee, G.S.; 2005. P-glycoprotein Inhibitor, Method for Preparing the Same and Pharmaceutical Composition Comprising the Same. PCT Int. Appl. WO 2005/033097 A1.
5. J.P. Bankstahl, M. Bankstahl, C. Kuntner, J. Stanek, T. Wanek, M. Meier, X. Ding, M. Müller, O. Langer, and W. Löscher A novel PET imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier J. Neurosci. 31 2011 8803 8811
6. 11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor Bioorg. Med. Chem. 18 2010 5489 5497
7. 11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data Clin. Pharmacol. Ther. 91 2012 227 233
8. M. Bergström, A. Grahnen, and B. Långström Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development Eur. J. Clin. Pharmacol. 59 2003 357 366 (Pubitemid 37214939)
9. C. Brandt, K. Bethmann, A.M. Gastens, and W. Löscher The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy Neurobiol. Dis. 24 2006 202 211 (Pubitemid 44416217)
10. M. Brunner, O. Langer, R. Sunder-Plassmann, G. Dobrozemsky, U. Müller, W. Wadsak, A. Krcal, R. Karch, C. Mannhalter, R. Dudczak, K. Kletter, I. Steiner, C. Baumgartner, and M. Müller Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans Clin. Pharmacol. Ther. 78 2005 182 190 (Pubitemid 41112286)
11. P. Chiba, G. Ecker, D. Schmid, J. Drach, B. Tell, S. Goldenberg, and V. Gekeler Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance Mol. Pharmacol. 49 1996 1122 1130
12. E.F. Choo, D. Kurnik, M. Muszkat, T. Ohkubo, S.D. Shay, J.N. Higginbotham, H. Glaeser, R.B. Kim, A.J. Wood, and G.R. Wilkinson Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier J. Pharmacol. Exp. Ther. 317 2006 1012 1018 (Pubitemid 43764103)
13. L. Cutler, C. Howes, N.J. Deeks, T.L. Buck, and P. Jeffrey Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier J. Pharm. Sci. 95 2006 1944 1953 (Pubitemid 44433026)
14. 11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier J. Med. Chem. 52 2009 6073 6082
15. E. Fox, and S.E. Bates Tariquidar (XR9576): a p-glycoprotein drug efflux pump inhibitor Expert Rev. Anticancer Ther. 7 2007 447 459 (Pubitemid 46681800)
16. K.M. Joo, K. Park, D.S. Kong, S.Y. Song, M.H. Kim, G.S. Lee, M.S. Kim, and D.H. Nam Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor Oncol. Rep. 19 2008 17 23 (Pubitemid 351176126)
17. P. Kannan, C. John, S.S. Zoghbi, C. Halldin, M.M. Gottesman, R.B. Innis, and M.D. Hall Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications Clin. Pharmacol. Ther. 86 2009 368 377
18. P. Kannan, S. Telu, S. Shukla, S.V. Ambudkar, V.W. Pike, C. Halldin, M.M. Gottesman, R.B. Innis, and M.D. Hall The specific P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2) ACS Chem. Neurosci. 2 2011 82 89
19. K. Kawamura, F. Konno, J. Yui, T. Yamasaki, A. Hatori, K. Yanamoto, H. Wakizaka, M. Takei, N. Nengaki, T. Fukumura, and M.R. Zhang Synthesis and evaluation of [(11)C]XR9576 to assess the function of drug efflux transporters using PET Ann. Nucl. Med. 24 2010 403 412
20. K. Kawamura, T. Yamasaki, F. Konno, J. Yui, A. Hatori, K. Yanamoto, H. Wakizaka, M. Takei, Y. Kimura, T. Fukumura, and M.R. Zhang Evaluation of limiting brain penetration related to p-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET in mice Mol. Imaging Biol. 13 2011 152 160
21. T.E. Kim, N. Gu, S.H. Yoon, J.Y. Cho, K.M. Park, S.G. Shin, I.J. Jang, and K.S. Yu Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies Clin. Ther. 34 2012 482 494
22. H. Kodaira, H. Kusuhara, J. Ushiki, E. Fuse, and Y. Sugiyama Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone J. Pharmacol. Exp. Ther. 333 2010 788 796
23. 11C-N-desmethyl-loperamide J. Nucl. Med. 51 2010 559 566
24. 11C] tariquidar in transporter knockout mice using small-animal PET [symposium abstract] Neuroimage 52 2010 S25
25. 11C]verapamil PET Eur. J. Nucl. Med. Mol. Imaging 37 2010 942 953
26. J.O. Kwak, S.H. Lee, G.S. Lee, M.S. Kim, Y.G. Ahn, J.H. Lee, S.W. Kim, K.H. Kim, and M.G. Lee Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel Eur. J. Pharmacol. 627 2010 92 98
27. 11C]verapamil J. Pharmacol. Exp. Ther. 316 2006 647 653 (Pubitemid 43130991)
28. W. Löscher, and H. Potschka Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases Prog. Neurobiol. 76 2005 22 76 (Pubitemid 41033402)
29. A.A. Lumen, P. Acharya, J.W. Polli, A. Ayrton, H. Ellens, and J. Bentz If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer? Drug Metab. Dispos. 38 2010 260 269
30. 11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats Nucl. Med. Biol. 36 2009 643 649
31. S. Mairinger, T. Erker, M. Müller, and O. Langer PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo Curr. Drug Metab. 12 2011 774 792
32. F.E. O'Brien, T.G. Dinan, B.T. Griffin, and J.F. Cryan Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings Br. J. Pharmacol. 165 2012 289 312
33. I.B. Paek, H.Y. Ji, M.S. Kim, G. Lee, and H.S. Lee Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/ electrospray mass spectrometry Rapid Commun. Mass Spectrom. 20 2006 1457 1462
34. H. Potschka Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport Adv. Drug Deliv. Rev. 64 2012 943 952
35. Sharp, M.J.; Mader, C.J.; Strachan, C.; 1998. Synthesis of Acridine Derivate Multidrug-Resistant Inhibitors. PCT Int. Appl. WO 98/52923 A1.
36. A. Spudich, E. Kilic, H. Xing, U. Kilic, K.M. Rentsch, H. Wunderli-Allenspach, C.L. Bassetti, and D.M. Hermann Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia Nat. Neurosci. 9 2006 487 488
37. E.A. van Vliet, R. van Schaik, P.M. Edelbroek, S. Redeker, E. Aronica, W.J. Wadman, N. Marchi, A. Vezzani, and J.A. Gorter Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats Epilepsia 47 2006 672 680
38. C.C. Wagner, and O. Langer Approaches using molecular imaging technology - use of PET in clinical microdose studies Adv. Drug. Deliv. Rev. 63 2011 539 546
39. 11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer Eur. J. Nucl. Med. Mol. Imaging 39 2012 149 159